AngioDynamics Ownership
| ANGO Stock | USD 12.46 0.05 0.40% |
Shares in Circulation | First Issued 2003-03-31 | Previous Quarter 40.7 M | Current Value 40.9 M | Avarage Shares Outstanding 30.2 M | Quarterly Volatility 9.7 M |
AngioDynamics |
AngioDynamics Stock Ownership Analysis
About 81.0% of the company shares are held by institutions such as insurance companies. The book value of AngioDynamics was presently reported as 5.09. The company has Price/Earnings To Growth (PEG) ratio of 1.87. AngioDynamics recorded a loss per share of 5.59. The entity had not issued any dividends in recent years. AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access and for use in oncology and surgical settings in the United States and internationally. The company was founded in 1988 and is headquartered in Latham, New York. Angiodynamics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 760 people. For more info on AngioDynamics please contact James Clemmer at 518 795 1400 or go to https://www.angiodynamics.com.Besides selling stocks to institutional investors, AngioDynamics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AngioDynamics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AngioDynamics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
AngioDynamics Quarterly Liabilities And Stockholders Equity |
|
AngioDynamics Insider Trades History
About 6.0% of AngioDynamics are currently held by insiders. Unlike AngioDynamics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AngioDynamics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of AngioDynamics' insider trades
AngioDynamics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AngioDynamics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AngioDynamics backward and forwards among themselves. AngioDynamics' institutional investor refers to the entity that pools money to purchase AngioDynamics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-09-30 | 810.4 K | Kent Lake Capital Llc | 2024-06-30 | 750 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 612.2 K | Jpmorgan Chase & Co | 2024-09-30 | 553.2 K | Assenagon Asset Management Sa | 2024-09-30 | 425.1 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 414.1 K | Acuitas Investments, Llc | 2024-09-30 | 403.3 K | Arnhold & S. Bleichroeder Advisers, Llc | 2024-09-30 | 394.1 K | Two Sigma Advisers, Llc | 2024-09-30 | 382.2 K | Blackrock Inc | 2024-09-30 | 4.7 M | Systematic Financial Management Lp | 2024-09-30 | 2.4 M |
AngioDynamics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AngioDynamics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AngioDynamics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AngioDynamics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AngioDynamics Outstanding Bonds
AngioDynamics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AngioDynamics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AngioDynamics bonds can be classified according to their maturity, which is the date when AngioDynamics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
AngioDynamics Corporate Filings
F4 | 17th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 16th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 4th of December 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with AngioDynamics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AngioDynamics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AngioDynamics will appreciate offsetting losses from the drop in the long position's value.Moving together with AngioDynamics Stock
Moving against AngioDynamics Stock
| 0.88 | HCAT | Health Catalyst | PairCorr |
| 0.68 | XAIR | Beyond Air | PairCorr |
| 0.66 | NRC | National Research Corp | PairCorr |
| 0.61 | VMD | Viemed Healthcare | PairCorr |
| 0.56 | TFX | Teleflex Incorporated | PairCorr |
The ability to find closely correlated positions to AngioDynamics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AngioDynamics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AngioDynamics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AngioDynamics to buy it.
The correlation of AngioDynamics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AngioDynamics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AngioDynamics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AngioDynamics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.59) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.